Verona seeks anti-cough partner following strong showing in the clinic
This article was originally published in Scrip
Verona Pharma will wait for ongoing discussions with potential investors or partners to bear fruit before continuing clinical development of VRP700, its promising anti-cough candidate, CEO Michael Walker (founder and former chairman of Canadian firm Cardiome Pharma) told Scrip.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.